Jefferies Financial Group Inc. Buys New Stake in Zevra Therapeutics, Inc. $ZVRA

Jefferies Financial Group Inc. acquired a new position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) in the 4th quarter, Holdings Channel reports. The fund acquired 120,000 shares of the company’s stock, valued at approximately $1,075,000.

Other large investors have also made changes to their positions in the company. Russell Investments Group Ltd. lifted its position in shares of Zevra Therapeutics by 235.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock worth $61,000 after purchasing an additional 4,475 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Zevra Therapeutics by 617.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock worth $88,000 after purchasing an additional 8,552 shares during the last quarter. Creative Planning acquired a new position in shares of Zevra Therapeutics during the 2nd quarter worth about $92,000. Qube Research & Technologies Ltd acquired a new stake in Zevra Therapeutics in the 2nd quarter worth $99,000. Finally, Quarry LP acquired a new stake in Zevra Therapeutics in the 3rd quarter worth $103,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

Zevra Therapeutics Stock Up 4.1%

Shares of ZVRA stock opened at $11.40 on Friday. Zevra Therapeutics, Inc. has a 12-month low of $7.16 and a 12-month high of $13.16. The company has a market capitalization of $673.97 million, a P/E ratio of 5.73 and a beta of 0.88. The firm has a 50-day moving average price of $10.10 and a 200 day moving average price of $9.29.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.12. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 51.49%. The firm had revenue of $36.22 million during the quarter, compared to the consensus estimate of $31.96 million. As a group, research analysts expect that Zevra Therapeutics, Inc. will post 0.56 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have issued reports on ZVRA. Wall Street Zen upgraded shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, April 11th. Guggenheim raised their price target on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Weiss Ratings lowered shares of Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research report on Friday, May 22nd. Finally, BTIG Research began coverage on shares of Zevra Therapeutics in a research report on Monday, March 16th. They issued a “buy” rating and a $23.00 price target on the stock. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Zevra Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $23.33.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.